Nashville’s Thyme Care raises $97 million in Series D funding
That brings the total capital raised since the company's founding in 2020 to $275 million.
Nashville-based Thyme Care, the leading value-based cancer care enabler, has announced a $97 million Series D fundraise from current investors CVS Health® Ventures, Foresite Capital, a16z Bio + Health, Concord Health Partners, Town Hall Ventures, AlleyCorp, and Frist Cressey Ventures.
New strategic investors include Morgan Health, a division of JPMorganChase focused on employer-sponsored healthcare, as well as Humana, Texas Oncology, and Memorial Hermann Health System, bringing Thyme Care’s total capital raised to $275 million.
“This raise is overwhelmingly backed by strategic investors across the oncology care delivery landscape, including payers, providers, employers, and health systems who deeply understand the complex needs of oncology populations and who see firsthand the impact of Thyme Care’s model,” said Brad Diephuis, MD, Thyme Care President and Chief Operating Officer. “This is evidence that oncology can lead the way in building scalable models of shared accountability and impact that healthcare has long needed.”
Since its founding by Robin Shah, Chief Executive Officer, and Dr. Bobby Green, Chief Medical Officer, in 2020, Thyme Care has grown from concept to market leader by creating an integrated oncology infrastructure that reduces friction across the system. Thyme Care aligns incentives through partnerships with payers so that the best care for patients is also the most sustainable for the system.
Like what you've read?
Forward to a friend!